Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease

This publication has 31 references indexed in Scilit:

• Long-Term Intravenous Treatment of Pompe Disease With Recombinant Human α-Glucosidase From Milk
  Pediatrics, 2004
• Recombinant human acid ??-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial
  Genetics in Medicine, 2001
• Recombinant human α-glucosidase from rabbit milk in Pompe patients
  The Lancet, 2000
• Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease
  Proceedings of the National Academy of Sciences, 2000
• Human Acid -Glucosidase from Rabbit Milk Has Therapeutic Effect in Mice with Glycogen Storage Disease Type II
  Human Molecular Genetics, 1999
• Recombinant Human Acid -Glucosidase: High Level Production in Mouse Milk, Biochemical Characteristics, Correction of Enzyme Deficiency in GSDII KO Mice
  Human Molecular Genetics, 1998
• Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
  Journal of Clinical Investigation, 1998
• High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease.
  Proceedings of the National Academy of Sciences, 1996
• Isolation and Characterisation of a Recombinant, Precursor form of Lysosomal Acid α‐Glucosidase
  European Journal of Biochemistry, 1995
• Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.
  Proceedings of the National Academy of Sciences, 1990